The National Cancer Institute (NCI)6, 17 recommends that dental professionals be considered part of the cancer care team for individuals undergoing cancer treatment and that people see their dentist 4 weeks prior to initiating cancer treatment (if possible) to allow for healing if any dental work is required.6, 17 The involvement of a dental team experienced with oral oncology may reduce the risk of oral complications, either by direct examination of the patient or in consultation with the patient’s community-based dentist.6 Dental work should generally prioritize treatment of teeth that have a risk of infection or decay to help avoid the need for dental treatment during cancer treatment.6, 17 According to the NCI, there is no universally accepted pre-cancer therapy dental protocol because of the lack of clinical trials evaluating the efficacy of a specific protocol.6 However, elimination of preexisting dental/periapical, periodontal, or mucosal infections; institution of comprehensive oral hygiene protocols during therapy; and reduction of other factors that may compromise oral mucosal integrity (e.g., physical trauma to oral tissues) may help reduce frequency and severity of oral complications in cancer patients.6 In some cases, such as acute leukemia, where induction chemotherapy may begin within days of diagnosis, there may be no time to institute elective dental therapy.18 On the other hand, in some cases of solid cancers (e.g., lung, breast, prostate, or colon cancer), there may be less of a need for urgent pretreatment dental evaluation if myelosuppression (specifically, neutropenia) is anticipated to be limited in severity.18, Given how common cancer is and the fact that cancer survival is increasing overall, it is likely that a dental health care provider will encounter people either with a history of cancer/cancer treatment or who are currently embarking on or undergoing treatment for cancer. Oral complications of cancer therapy can be acute (i.e., developing during treatment) or delayed onset (i.e., developing , Patients at increased risk of MRONJ include those: receiving antiresorptive agents at dosages and treatment schedules associated with cancer-related indications; receiving antiresorptive drugs for more than 2 years; receiving antiresorptive therapy in conjunction with antiangiogenic drugs for cancer; with periodontitis or dentures..